Corvus Pharmaceuticals Inc.

0.9650+0.1035+12.01%Vol 487.04K1Y Perf -57.77%
Aug 11th, 2022 16:00 DELAYED
BID0.9300 ASK0.9900
Open0.9000 Previous Close0.8615
Pre-Market- After-Market0.94
 - -  -0.03 -3.11%
Target Price
6.38 
Analyst Rating
Strong Buy 1.00
Potential %
561.14 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/83 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/-95 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/-80 
Income Ranking
 —    -
Price Range Ratio 52W %
2.44 
Earnings Rating
Strong Sell
Market Cap44.92M 
Earnings Date
8th Aug 2022
Alpha-0.02 Standard Deviation0.27
Beta1.03 

Today's Price Range

0.86100.9900

52W Range

0.75019.54

5 Year PE Ratio Range

-9.30-3.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
5.35%
1 Month
-10.65%
3 Months
-7.21%
6 Months
-49.74%
1 Year
-57.77%
3 Years
-76.00%
5 Years
-91.74%
10 Years
-

TickerPriceChg.Chg.%
CRVS0.96500.103512.01
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.19-0.185.26
Q01 2022-0.14-0.18-28.57
Q04 2021-0.20-0.200.00
Q03 2021-0.30-0.2420.00
Q02 2021-0.32-0.2812.50
Q01 2021-0.33-0.34-3.03
Q04 2020-0.32-0.35-9.38
Q03 2020-0.25-0.33-32.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.19-11.76Negative
9/2022 QR-0.26-8.33Negative
12/2022 FY-0.88-4.76Negative
12/2023 FY-1.2420.51Positive
Next Report Date-
Estimated EPS Next Report-0.19
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume487.04K
Shares Outstanding46.55K
Shares Float34.60M
Trades Count1.31K
Dollar Volume441.78K
Avg. Volume414.57K
Avg. Weekly Volume627.18K
Avg. Monthly Volume333.59K
Avg. Quarterly Volume282.94K

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) stock closed at 0.965 per share at the end of the most recent trading day (a 12.01% change compared to the prior day closing price) with a volume of 487.04K shares and market capitalization of 44.92M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Corvus Pharmaceuticals Inc. CEO is Richard A. Miller.

The one-year performance of Corvus Pharmaceuticals Inc. stock is -57.77%, while year-to-date (YTD) performance is -59.96%. CRVS stock has a five-year performance of -91.74%. Its 52-week range is between 0.7501 and 9.54, which gives CRVS stock a 52-week price range ratio of 2.44%

Corvus Pharmaceuticals Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.51, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -39.09%, a ROC of -42.16% and a ROE of -44.68%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Corvus Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. Corvus Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Corvus Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6.38, which is +561.14% compared to the current price. The earnings rating for Corvus Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Corvus Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Corvus Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.49, ATR14 : 0.09, CCI20 : 8.79, Chaikin Money Flow : -0.26, MACD : -0.03, Money Flow Index : 46.48, ROC : 7.23, RSI : 41.09, STOCH (14,3) : 79.66, STOCH RSI : 1.00, UO : 47.86, Williams %R : -20.34), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Corvus Pharmaceuticals Inc. in the last 12-months were: Leiv Lea (Buy at a value of $77 045), Peter A. Thompson (Sold 1 109 644 shares of value $6 757 732 ), Richard A. Miller (Buy at a value of $104 320)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing small-molecule and antibody agents that target the immune system to treat patients with cancer. The firm's pipeline includes CPI-006, CPI-818, CPI-935, and others.

CEO: Richard A. Miller

Telephone: +1 650 900-4520

Address: 863 Mitten Road, Burlingame 94010, CA, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

38%62%

Bearish Bullish

58%42%

TipRanks News for CRVS

Fri, 11 Mar 2022 11:28 GMT Corvus Pharmaceuticals (CRVS) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Fri, 11 Mar 2022 01:25 GMT Corvus Pharmaceuticals (CRVS) Gets a Hold Rating from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits